Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Combination Product Review Assignment Should Consider Precedent – Abbott

Executive Summary

FDA's combination product review rule should take precedent into account in assigning drug and diagnostic products used together, Abbott says

You may also be interested in...



Combo Products Primary Mode Of Action Rule Takes Effect In November

FDA is revisiting its Intercenter Agreements on combination product jurisdictions in light of its final rule defining primary mode of action

Combo Products Primary Mode Of Action Rule Takes Effect In November

FDA is revisiting its Intercenter Agreements on combination product jurisdictions in light of its final rule defining primary mode of action

Combo Product Filer Can Contact FDA If First Action Date Missed – Guidance

For a combination product being reviewed under two separate applications, the sponsor can file a dispute resolution request to the Office of Combination Products once the first of the two action dates has passed

Related Content

Topics

UsernamePublicRestriction

Register

ID020288

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel